Laurel Wealth Planning’s AbbVie ABBV Stock Holding History

Laurel Wealth Planning’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,031	Closed	-$236K	–	60
2025 Q4	$236K	Buy	+1,031	New	+$235K	0.13%	54
2025 Q3	–	Sell	-1,128	Closed	-$209K	–	58
2025 Q2	$209K	Hold	1,128	–	–	0.12%	55
2025 Q1	$236K	Hold	1,128	–	–	0.16%	49
2024 Q4	$200K	Hold	1,128	–	–	0.13%	54
2024 Q3	$223K	Buy	+1,128	New	+$211K	0.15%	52
2024 Q2	–	Sell	-1,128	Closed	-$205K	–	52
2024 Q1	$205K	Buy	+1,128	New	+$194K	0.14%	53
2023 Q2	–	Sell	-1,285	Closed	-$205K	–	55
2023 Q1	$205K	Sell	1,285 -147	-10%	-$22.5K	0.14%	57
2022 Q4	$231K	Hold	1,432	–	–	0.15%	56
2022 Q3	$192K	Hold	1,432	–	–	0.14%	56
2022 Q2	$219K	Sell	1,432 -225	-14%	-$34.4K	0.15%	56
2022 Q1	$269K	Buy	1,657 +1,500	+955%	+$218K	0.18%	63
2021 Q4	$21K	Hold	157	–	–	0.02%	113
2021 Q3	$17K	Buy	157 +100	+175%	+$11.4K	0.01%	117
2021 Q2	$6K	Hold	57	–	–	0.01%	104
2021 Q1	$6K	Hold	57	–	–	0.01%	98
2020 Q4	$6K	Buy	+57	New	+$5.48K	0.01%	91

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Laurel Wealth Planning's ABBV Position: Q1 2026 in Review

Laurel Wealth Planning sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,031 shares — an estimated $236K sold.

Laurel Wealth Planning first reported a position in ABBV in Q4 2020 and held it in 16 quarters. The position peaked at $269K in Q1 2022. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Laurel Wealth Planning reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Laurel Wealth Planning sold 1,031 AbbVie shares in Q1 2026, an estimated $236K.
Laurel Wealth Planning first reported a position in AbbVie in Q4 2020 and held it in 16 quarters.
Laurel Wealth Planning's AbbVie position peaked at $269K in Q1 2022.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Laurel Wealth Planning's 13F filing for Q1 2026, filed 23 Apr 2026.